GlaxoSmithKline plc (the 'Company')
Transaction notification
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Ms E Walmsley |
|||
|
b) |
Position/status |
Chief Executive Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£16.7434 |
7 (partnership shares) |
|
||
|
|
£16.7434 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £16.7434 |
||||
|
e) |
Date of the transaction |
2019-08-09 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr R Connor |
|||
|
b) |
Position/status |
President, Global Vaccines |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£16.7434 |
7 (partnership shares) |
|
||
|
|
£16.7434 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £16.7434 |
||||
|
e) |
Date of the transaction |
2019-08-09 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr N Hirons |
|||
|
b) |
Position/status |
SVP, Global Ethics and Compliance |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£16.7434 |
7 (partnership shares) |
|
||
|
|
£16.7434 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £16.7434 |
||||
|
e) |
Date of the transaction |
2019-08-09 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Ms S Jackson |
|||
|
b) |
Position/status |
SVP, Global Communications and CEO Office |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£16.7434 |
7 (partnership shares) |
|
||
|
|
£16.7434 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £16.7434 |
||||
|
e) |
Date of the transaction |
2019-08-09 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr D Jackson |
|||
|
b) |
Position/status |
PCA of Ms S Jackson (SVP, Global Communications and CEO Office) |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£16.7434 |
7 (partnership shares) |
|
||
|
|
£16.7434 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £16.7434 |
||||
|
e) |
Date of the transaction |
2019-08-09 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr D Redfern |
|||
|
b) |
Position/status |
Chief Strategy Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£16.7434 |
7 (partnership shares) |
|
||
|
|
£16.7434 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £16.7434 |
||||
|
e) |
Date of the transaction |
2019-08-09 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr R Simard |
|||
|
b) |
Position/status |
President, Pharmaceuticals Supply Chain |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£16.7434 |
7 (partnership shares) |
|
||
|
|
£16.7434 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £16.7434 |
||||
|
e) |
Date of the transaction |
2019-08-09 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr P Thomson |
|||
|
b) |
Position/status |
President, Global Affairs |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£16.7434 |
8 (partnership shares) |
|
||
|
|
£16.7434 |
8 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
16 Ordinary Shares £16.7434 |
||||
|
e) |
Date of the transaction |
2019-08-09 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Ms V Whyte |
|||
|
b) |
Position/status |
Company Secretary |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£16.7434 |
7 (partnership shares) |
|
||
|
|
£16.7434 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £16.7434 |
||||
|
e) |
Date of the transaction |
2019-08-09 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
